Copyright
©The Author(s) 2017.
World J Clin Cases. Sep 16, 2017; 5(9): 349-359
Published online Sep 16, 2017. doi: 10.12998/wjcc.v5.i9.349
Published online Sep 16, 2017. doi: 10.12998/wjcc.v5.i9.349
Clinical conditions | Glycemic goals |
> 10 yr of life expectancy | HbA1c < 7% |
Good medical support | Fasting plasma glucose < 7 mmol/L |
High expected benefit from treatment | Postprandial blood glucose < 10.0 mmol/L |
Low hypoglycaemia risk | Stabile blood glucose level |
> 10 yr of life expectancy | HbA1c = 7% |
New diagnosed and relatively young | |
No syndromes or complications | |
Low risk of treatment-related hypoglycaemia | |
Not using glycaemic-lowering medications or only use one type of non-insulin secretagogues | |
Good treatment adherence | |
> 10 yr life expectancy | HbA1c < 7.5% |
Type I or type II diabetes | |
Mild syndromes or complications | |
Moderate risk of treatment-related hypoglycaemia | |
Receiving insulin secretagogues or insulin therapy | |
< 5 yr of life expectancy | HbA1c < 8% |
Moderate syndromes or complications | |
Moderate risk of hypoglycaemia | |
Receiving insulin secretagogues or primarily multiple insulin injections | |
< 5 yr of life expectancy | HbA1c < 8.5% |
Incapable to self-manage | Avoid acute diabetic complications or refractory infections caused by severe hyperglycaemia |
Blood glucose < 11.1 mmol/L |
- Citation: Yong J, Lin D, Tan XR. Primary prevention of cardiovascular disease in older adults in China. World J Clin Cases 2017; 5(9): 349-359
- URL: https://www.wjgnet.com/2307-8960/full/v5/i9/349.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v5.i9.349